Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 60, Issue 3, 2015, Pages 360-367

  Corey, Kathleen E ^a   Vuppalanchi, Raj ^b   Vos, Miriam ^c   Kohli, Rohit ^d   Molleston, Jean P ^b   Wilson, Laura ^e   Unalp Arida, Aynur ^e   Cummings, Oscar W ^b   Lavine, Joel E ^f   Chalasani, Naga ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

cardiovascular disease risk; lipids; metformin; non high density lipoprotein cholesterol; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADOLESCENT; ARTICLE; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; HISTOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; BIOPSY; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COHORT ANALYSIS; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIAS; FEMALE; LIVER; LONGITUDINAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK FACTOR; UNITED STATES;

ADOLESCENT; BIOMARKERS; BIOPSY; CARDIOVASCULAR DISEASES; CHILD; COHORT STUDIES; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; LIVER; LONGITUDINAL STUDIES; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; REMISSION INDUCTION; REMISSION, SPONTANEOUS; RISK FACTORS; UNITED STATES;

EID: 84926344564     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000584     Document Type: Article

References (40)

1. Mencin AA, Lavine JE. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2011; 14: 151-7
2. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-93
3. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-Alcoholic fatty liver disease in children: a followup study for up to 20 years. Gut 2009; 58: 1538-44
4. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8
5. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21
6. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-Alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008; 51: 1947-53
7. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602
8. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-Term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73
9. Schwimmer JB, Pardee PE, Lavine JE, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008; 118: 277-83
10. Alkhouri N, Carter-Kent C, Elias M, et al. Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clin Lipidol 2011; 6: 305-14
11. Cali AM, Zern TL, Taksali SE, et al. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. Diabetes Care 2007; 30: 3093-8
12. Nobili V, Alkhouri N, Bartuli A, et al. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res 2010; 67: 665-70
13. Demircioglu F, Kocyigit A, Arslan N, et al. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008; 47: 68-75
14. Pacifico L, Cantisani V, Ricci P, et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 2008; 63: 423-7
15. Gokce S, Atbinici Z, Aycan Z, et al. The relationship between pediatric nonalcoholic fatty liver disease and cardiovascular risk factors and increased risk of atherosclerosis in obese children. Pediatr Cardiol 2013; 34: 308-15
16. Cho T, Kim YJ, Paik SS. The efficacy of pharmacological treatment in pediatric nonalcoholic fatty liver disease pediatric gastroenterology. J Pediatr Gastroenterol Nutr 2012; 15: 256-65
17. de Piano A, Prado WL, Caranti DA, et al. Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2007; 44: 446-52
18. de Piano A, de Mello MT, Sanches Pde L, et al. Long-Term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents. Eur J Gastroenterol Hepatol 2012; 24: 1313-24
19. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119-28
20. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009; 55: 35-41
21. Corey KE, Lai M, Gelrud L, et al. Non-high density lipoprotein cholesterol as a biomarker for non-Alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2012; 10: 651-6
22. Robinson JG. Are you targeting non-high-density lipoprotein cholesterol?. J Am Coll Cardiol 2009; 55: 42-4
23. Robinson JG, Wang S, Smith BJ, et al. Meta-Analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009; 53: 316-22
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421
25. Srinivasan SR, Frontini MG, Xu J, et al. Utility of childhood non-highdensity lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics 2006; 118: 201-6
26. McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000; 20: 1998-2004
27. Stan S, Levy E, Delvin EE, et al. Distribution of LDL particle size in a population-based sample of children and adolescents and relationship with other cardiovascular risk factors. Clin Chem 2005; 51: 1192-200
28. Burns SF, Lee SJ, Arslanian SA. Surrogate lipid markers for small dense low-density lipoprotein particles in overweight youth. J Pediatr 2012; 161: 991-6
29. Hannon TS, Bacha F, Lee SJ, et al. Use of markers of dyslipidemia to identify overweight youth with insulin resistance. Pediatr Diabetes 2006; 7: 260-6
30. Giannini C, Santoro N, Caprio S, et al. The triglyceride-To-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care 2011; 34: 1869-74
31. Urbina EM, Khoury PR, McCoy CE, et al. Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults. Pediatrics 2013; 131: e1082-90
32. Shah AS, Urbina EM, Khoury PR, et al. Lipids and lipoprotein ratios: contribution to carotid intima media thickness in adolescents and young adults with type 2 diabetes mellitus. J Clin Lipidol 2013; 7: 441-5
33. Morrison JA, Glueck CJ, Woo JG, et al. Risk factors for cardiovascular disease and type 2 diabetes retained from childhood to adulthood predict adult outcomes: the Princeton LRC Follow-Up Study. Int J Pediatr Endocrinol 2012; 2012: 6
34. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-68
35. Lavine JE, Schwimmer JB, Molleston JP, et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010; 31: 62-70
36. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21
37. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 (suppl 5): S213-56
38. Klotzsch SG, McNamara JR. Triglyceride measurements: a review of methods and interferences. Clin Chem 1990; 36: 1605-13
39. Jessen RH, Dass CJ, Eckfeldt JH. Do enzymatic analyses of serum triglycerides really need blanking for free glycerol?. Clin Chem 1990; 36: 1372-5
40. Jin R, Le NA, Liu S, et al. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab 2012; 97: E1088-9